Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 11/20 | 0.43 |
| ▸ | PLK1 | P53350 | 13/20 | 0.42 |
| ▸ | CMA1 | P23946 | 2/20 | 0.41 |
| ▸ | AHR | P35869 | 2/20 | 0.41 |
| ▸ | INSR | P06213 | 3/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30993146 | 0.85 | CYP11B1 (0.46) | PDE3BPDE3A | |
| SCHEMBL26604838 | 0.83 | MAPT (0.42) | — | |
| Acetic Acid SCHEMBL26604909 | 0.79 | CYP11B1 (0.44) | — | |
| SCHEMBL19153946 | 0.77 | AHR (0.44) | EIF2AK2KDRPLK1CMA1AHR | |
| SCHEMBL24127411 | 0.75 | CHRNB2 (0.37) | KDRPLK1EGFRSRCPDE3B | |
| SCHEMBL30133714 | 0.75 | CHRNB2 (0.37) | KDRPLK1EGFRSRCPDE3B | |
| SCHEMBL8344102 | 0.75 | CYP11B1 (0.49) | PDE3BPDE3A | |
| SCHEMBL16291500 | 0.75 | SMYD3 (0.43) | EIF2AK2KDRPLK1INSRPTK2 | |
| SCHEMBL29878803 | 0.75 | SMYD3 (0.43) | EIF2AK2KDRPLK1INSRPTK2 | |
| SCHEMBL1898056 | 0.75 | CYP1A2 (0.58) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012022707-A1 | SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-23 | — | — | WO | disclosed |
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| WO-2011092293-A2 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | CRHR1, CRHR2, CRH | EIF2AK2 1976/4885KDR 1054/4885PLK1 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.